Rocket Pharmaceuticals Securities Fraud Lawsuit: Investors with Losses Over $100K Can Lead Class Action

Rocket Pharmaceuticals investors who suffered losses over $100K have until August 11, 2025, to file a lawsuit against the company. The lawsuit alleges that Rocket Pharmaceuticals made false statements about its RP-A501 clinical trial protocol, leading to increased risk of serious adverse events. Investors may be eligible for compensation without payment of fees or costs through a contingency fee arrangement.

Investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) who suffered losses exceeding $100,000 are urged to file a lawsuit by August 11, 2025. The lawsuit alleges that the company made false statements about its RP-A501 clinical trial protocol, leading to increased risk of serious adverse events. Investors may be eligible for compensation without payment of fees or costs through a contingency fee arrangement.

The class action lawsuit, filed in the United States District Court for the District of New Jersey, centers on Rocket Pharmaceuticals' disclosures about the trial protocol of its RP-A501 Phase 2 pivotal trial. The lawsuit claims that the company misled investors by not disclosing significant protocol changes and the potential for serious adverse events (SAEs), including patient deaths [1].

On May 27, 2025, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration had placed a clinical hold on the RP-A501 trial following a patient's SAE and subsequent death. The company's stock price plummeted 62% in a single day and down 75% from its February 27, 2025 closing price [1].

The lawsuit alleges that Rocket Pharmaceuticals made materially false and misleading statements regarding the safety, efficacy, and clinical protocol of its RP-A501 Phase 2 pivotal trial. The company's shares closed at $9.40 on February 27, 2025, buoyed by statements that highlighted progress in advancing the gene therapy and cited the Phase 1 results of RP-A501 as evidence of safety and meaningful efficacy up to five years [1].

Investors who purchased Rocket Pharmaceuticals securities between September 17, 2024 and May 26, 2025, both dates inclusive, may be eligible to join the class action lawsuit. To join, investors can visit the Rosen Law Firm's website or contact Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com [2].

The Rosen Law Firm, a global investor rights law firm, encourages investors to select qualified counsel with a track record of success in leadership roles. The firm has secured hundreds of millions of dollars for investors and has been ranked in the top 4 each year since 2013 [2].

Investors are advised to act promptly, as the deadline to seek lead plaintiff status is August 11, 2025. If you wish to serve as lead plaintiff, you must move the Court no later than this date [2].

References:
[1] https://www.globenewswire.com/news-release/2025/08/08/3130175/32716/en/Rocket-Pharmaceuticals-Inc-RCKT-Faces-Securities-Class-Action-Amid-Protocol-Change-and-FDA-s-Clinical-Hold-on-Gene-Therapy-Trial-Hagens-Berman.html
[2] https://www.globenewswire.com/news-release/2025/08/10/3130551/673/en/RCKT-DEADLINE-TOMORROW-ROSEN-SKILLED-INVESTOR-COUNSEL-Encourages-Rocket-Pharmaceuticals-Inc-Investors-with-Losses-in-Excess-of-100K-to-Secure-Counsel-Before-Important-August-11-Dea.html